BioPharmSignal logoBioPharmSignal

Biotech News

Replimune Reports Fiscal Second Quarter 2027 Financial Results and Provides Corporate Update

Replimune Group (REPL)Replimune GroupEarnings

TUDRIQEV first delivered to patients for advanced melanoma on October 6th More than 15 institutions have prescribed TUDRIQEV Management will host a webcast today at 8:00 a.m. ET WOBURN, Mass., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a commercial stage biotechnology

Related news

REPLReplimune Group2026-10-22 12:00 EST

Replimune to Report the Fiscal Second Quarter 2027 Financial Results and Provide Corporate Update on October 28, 2026

RVMDRevolution Medicines2026-11-04 21:02 EST

Revolution Medicines Reports Third Quarter 2026 Financial Results and Update on Corporate Progress

EXELExelixis2026-10-29 20:05 EST

Exelixis Announces Third Quarter 2026 Financial Results and Provides Corporate Update

RLAYRelay Therapeutics2026-10-28 20:12 EST

Relay Therapeutics to Announce Third Quarter 2026 Financial Results and Corporate Highlights on November 4, 2026

BNTXBioNTech2026-10-20 10:45 EST

BioNTech to Report Third Quarter 2026 Financial Results and Corporate Update on November 3, 2026

NRIXNurix Therapeutics2026-10-12 20:05 EST

Nurix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

ANGOAngioDynamics2026-10-08 10:02 EST

AngioDynamics Reports Fiscal Year 2027 First Quarter Financial Results; Continued Execution Drives Med Tech Growth and Profitability

IMCRImmunocore Holdings plc2026-11-06 14:00 EST

Immunocore reports third quarter financial results and provides a business update

COGTCogent Biosciences2026-11-05 21:02 EST

Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2026 Financial Results

FATEFate Therapeutics2026-11-05 12:00 EST

Fate Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates

View all latest news

Replimune Group

Oncolytic Immunotherapy Platform Replimune develops engineered herpes-simplex-virus-based immunotherapies that selectively replicate within tumors, directly destroy cancer cells, release tumor antigens, and stimulate systemic antitumor immunity. Its viruses are armed with immune-activating components intended to enhance local tumor...

Recent company news

REPLReplimune Group2026-10-28 11:00 EST

Replimune Reports Fiscal Second Quarter 2027 Financial Results and Provides Corporate Update

REPLReplimune Group2026-10-22 12:00 EST

Replimune to Report the Fiscal Second Quarter 2027 Financial Results and Provide Corporate Update on October 28, 2026

REPLReplimune Group2026-10-01 20:01 EST

Replimune Announces TUDRIQEV™ Now Available in the U.S. for Advanced Melanoma

REPLReplimune Group2026-09-03 12:00 EST

Replimune to Present at the Cantor Global Healthcare Conference 2026

REPLReplimune Group2026-08-19 20:01 EST

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Stock data

Close
20.02 USD
Market cap
732.42M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States